A novel case series explores the clinical efficacy of enamel matrix derivative in human pulp-dentin regeneration A recent case series reports encouraging clinical and radiographic outcomes following the use of Emdogain® (Straumann®, Switzerland), an enamel matrix derivative (EMD), as a biologic scaffold in regenerative endodontic procedures (REPs). While EMD has demonstrated regenerative potential in preclinical studies by modulating odontogenic and angiogenic pathways, this is among the first documented applications in human REP cases.
Clinical Background:
Three pediatric patients (two males, one female), aged 8, 8, and 12 years, from São Luís, Maranhão, Brazil, presented with necrotic pulps in immature permanent teeth and were treated using a standardized two-visit regenerative endodontic protocol. The intervention included canal disinfection, induction of apical bleeding, and placement of EMD (Emdogain®) into the canal space to facilitate pulp tissue regeneration.Clinical Protocol and Assessments:
- Subjective pain intensity was evaluated using the Visual Analogue Scale (VAS) at baseline and 7 days post-operatively.
- Crown shade stability was measured using a VITA Easyshade® Advance 4.0 spectrophotometer.
- Periapical healing and root development parameters were assessed radiographically at 12 and 24 months.
Free for members
Keep reading — it's free
The rest of this article is open to DentalReach members. Create a free account, or sign in, and every article on the site opens in full.